{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:10:57Z","timestamp":1767985857353,"version":"3.49.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11033-024-09291-1","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T16:02:06Z","timestamp":1708444926000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Herbal-based therapeutics for diabetic patients with SARS-Cov-2 infection"],"prefix":"10.1007","volume":"51","author":[{"given":"Yousef","family":"Rasmi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ighli","family":"di Bari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shah","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munima","family":"Haque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pornanong","family":"Aramwit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elmira","family":"Roshani Asl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"issue":"7","key":"9291_CR1","volume":"36","author":"W Guo","year":"2020","unstructured":"Guo W et al (2020) Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes\/Metab Res Rev 36(7):e3319","journal-title":"Diabetes\/Metab Res Rev"},{"issue":"12","key":"9291_CR2","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.3390\/molecules24122277","volume":"24","author":"M Imran","year":"2019","unstructured":"Imran M et al (2019) Kaempferol: a key emphasis to its anticancer potential. Molecules 24(12):2277","journal-title":"Molecules"},{"key":"9291_CR3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fphar.2013.00177","volume":"4","author":"M Ekor","year":"2014","unstructured":"Ekor M (2014) The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol 4:177","journal-title":"Front Pharmacol"},{"key":"9291_CR4","first-page":"2020030226","volume":"2020","author":"S Khaerunnisa","year":"2020","unstructured":"Khaerunnisa S et al (2020) Potential inhibitor of COVID-19 main protease (Mpro) from several medicinal plant compounds by molecular docking study. Preprints 2020:2020030226","journal-title":"Preprints"},{"issue":"3","key":"9291_CR5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3164\/jcbn.40.163","volume":"40","author":"M Modak","year":"2007","unstructured":"Modak M et al (2007) Indian herbs and herbal drugs used for the treatment of diabetes. J Clin Biochem Nutr 40(3):163\u2013173","journal-title":"J Clin Biochem Nutr"},{"key":"9291_CR6","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107843","volume":"157","author":"P Saeedi","year":"2019","unstructured":"Saeedi P et al (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract 157:107843","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"9291_CR7","first-page":"151","volume":"33","author":"MM Lima-Mart\u00ednez","year":"2021","unstructured":"Lima-Mart\u00ednez MM et al (2021) COVID-19 and diabetes: a bidirectional relationship. Clin Investig Arterioscler 33(3):151\u2013157","journal-title":"Clin Investig Arterioscler"},{"key":"9291_CR8","volume":"8","author":"HM Al-kuraishy","year":"2021","unstructured":"Al-kuraishy HM et al (2021) COVID-19 in relation to hyperglycemia and diabetes mellitus. Front Cardiovasc Med 8:644095","journal-title":"Front Cardiovasc Med"},{"key":"9291_CR9","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108296","volume":"166","author":"LJ Sacks","year":"2020","unstructured":"Sacks LJ et al (2020) Considerations for people with diabetes during the Coronavirus Disease (COVID-19) pandemic. Diabetes Res Clin Pract 166:108296","journal-title":"Diabetes Res Clin Pract"},{"key":"9291_CR10","volume":"144","author":"Y Li","year":"2021","unstructured":"Li Y et al (2021) Follow-up study of pulmonary sequelae in discharged COVID-19 patients with diabetes or secondary hyperglycemia. Eur J Radiol 144:109997","journal-title":"Eur J Radiol"},{"issue":"11","key":"9291_CR11","doi-asserted-by":"crossref","first-page":"6555","DOI":"10.3390\/ijerph19116555","volume":"19","author":"T G\u0119ca","year":"2022","unstructured":"G\u0119ca T et al (2022) Increased risk of COVID-19 in patients with diabetes mellitus\u2014current challenges in pathophysiology, treatment and prevention. Int J Environ Res Public Health 19(11):6555","journal-title":"Int J Environ Res Public Health"},{"key":"9291_CR12","first-page":"9062107","volume":"2017","author":"SM Fernando","year":"2017","unstructured":"Fernando SM, Cardinal P, Brindley PG (2017) Hypoxemic respiratory failure from acute respiratory distress syndrome secondary to leptospirosis. Case Rep Crit Care 2017:9062107","journal-title":"Case Rep Crit Care"},{"issue":"11","key":"9291_CR13","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1016\/j.cmet.2021.09.009","volume":"33","author":"M Reiterer","year":"2021","unstructured":"Reiterer M et al (2021) Hyperglycemia in acute COVID-19 is characterized by insulin resistance and adipose tissue infectivity by SARS-CoV-2. Cell Metab 33(11):2174-2188.e5","journal-title":"Cell Metab"},{"issue":"6","key":"9291_CR14","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.cmet.2020.04.021","volume":"31","author":"L Zhu","year":"2020","unstructured":"Zhu L et al (2020) Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing Type 2 diabetes. Cell Metab 31(6):1068-1077.e3","journal-title":"Cell Metab"},{"issue":"7","key":"9291_CR15","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.2337\/dc20-0723","volume":"43","author":"C Sardu","year":"2020","unstructured":"Sardu C et al (2020) Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control? Diabetes Care 43(7):1408\u20131415","journal-title":"Diabetes Care"},{"issue":"10","key":"9291_CR16","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S2213-8587(20)30272-2","volume":"8","author":"E Barron","year":"2020","unstructured":"Barron E et al (2020) Associations of Type 1 and Type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol 8(10):813\u2013822","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"9291_CR17","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1007\/s00125-020-05180-x","volume":"63","author":"B Cariou","year":"2020","unstructured":"Cariou B et al (2020) Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia 63(8):1500\u20131515","journal-title":"Diabetologia"},{"issue":"1","key":"9291_CR18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s43168-021-00099-2","volume":"15","author":"RAI Reshad","year":"2021","unstructured":"Reshad RAI et al (2021) Diabetes in COVID-19 patients: challenges and possible management strategies. Egypt J Bronchol 15(1):53","journal-title":"Egypt J Bronchol"},{"issue":"1\u20132","key":"9291_CR19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/08830185.2020.1844195","volume":"40","author":"RC Borges","year":"2021","unstructured":"Borges RC, Hohmann MS, Borghi SM (2021) Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome. Int Rev Immunol 40(1\u20132):108\u2013125","journal-title":"Int Rev Immunol"},{"key":"9291_CR20","first-page":"1","volume":"21","author":"HM Alhuthali","year":"2023","unstructured":"Alhuthali HM et al (2023) Neutrophilia and its correlation with increased inflammatory response in COVID-19 in diabetic and pre-diabetic patients. Eur J Inflamm 21:1\u20138","journal-title":"Eur J Inflamm"},{"key":"9291_CR21","volume":"12","author":"M Han","year":"2021","unstructured":"Han M et al (2021) Immunological characteristics in Type 2 diabetes mellitus among COVID-19 patients. Front Endocrinol (Lausanne) 12:596518","journal-title":"Front Endocrinol (Lausanne)"},{"key":"9291_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcvm.2018.00001","volume":"5","author":"N Pechlivani","year":"2018","unstructured":"Pechlivani N, Ajjan RA (2018) Thrombosis and vascular inflammation in diabetes: mechanisms and potential therapeutic targets. Front Cardiovasc Med 5:1","journal-title":"Front Cardiovasc Med"},{"key":"9291_CR23","doi-asserted-by":"crossref","DOI":"10.1016\/j.mvr.2021.104310","volume":"140","author":"R Basra","year":"2022","unstructured":"Basra R et al (2022) What is the impact of microvascular complications of diabetes on severe COVID-19? Microvasc Res 140:104310","journal-title":"Microvasc Res"},{"issue":"3","key":"9291_CR24","doi-asserted-by":"crossref","first-page":"H403","DOI":"10.1152\/ajpheart.00204.2022","volume":"323","author":"C AlugantiNarasimhulu","year":"2022","unstructured":"AlugantiNarasimhulu C, Singla DK (2022) Mechanisms of COVID-19 pathogenesis in diabetes. Am J Physiol Heart Circ Physiol 323(3):H403\u2013H420","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"9291_CR25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11892-007-0041-3","volume":"7","author":"S Pennathur","year":"2007","unstructured":"Pennathur S, Heinecke JW (2007) Oxidative stress and endothelial dysfunction in vascular disease. Curr Diab Rep 7(4):257\u2013264","journal-title":"Curr Diab Rep"},{"issue":"10","key":"9291_CR26","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.3390\/medicina57101072","volume":"57","author":"JL Burgess","year":"2021","unstructured":"Burgess JL et al (2021) Diabetic wound-healing science. Medicina 57(10):1072","journal-title":"Medicina"},{"issue":"Sup2","key":"9291_CR27","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.12968\/jowc.2021.30.Sup2.S12","volume":"30","author":"A Oropallo","year":"2021","unstructured":"Oropallo A et al (2021) Wound care during the COVID-19 pandemic: improving outcomes through the integration of telemedicine. J Wound Care 30(Sup2):S12\u2013S17","journal-title":"J Wound Care"},{"key":"9291_CR28","doi-asserted-by":"crossref","unstructured":"Cheng Y et al (2020) Kidney impairment is associated with in-hospital death of COVID-19 patients. medRxiv 2020.02.18.20023242","DOI":"10.1101\/2020.02.18.20023242"},{"key":"9291_CR29","doi-asserted-by":"crossref","first-page":"6666086","DOI":"10.1155\/2021\/6666086","volume":"2021","author":"S Khalili","year":"2021","unstructured":"Khalili S et al (2021) Prevalence, risk factors and outcomes associated with acute kidney injury in patients hospitalized for COVID-19: a comparative study between diabetic and nondiabetic patients. J Diabetes Res 2021:6666086","journal-title":"J Diabetes Res"},{"key":"9291_CR30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3389\/fmed.2020.00199","volume":"7","author":"L D'Marco","year":"2020","unstructured":"D\u2019Marco L et al (2020) Diabetic kidney disease and COVID-19: the crash of two pandemics. Front Med (Lausanne) 7:199","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"9291_CR31","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3390\/medicina58050644","volume":"58","author":"F Abdulaziz Al-Muhanna","year":"2022","unstructured":"Abdulaziz Al-Muhanna F et al (2022) Impact of COVID-19 on kidney of diabetic patients. Medicina (Kaunas) 58(5):644","journal-title":"Medicina (Kaunas)"},{"issue":"10","key":"9291_CR32","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S2213-8587(21)00241-2","volume":"9","author":"P Vellanki","year":"2021","unstructured":"Vellanki P, Umpierrez GE (2021) Diabetic ketoacidosis risk during the COVID-19 pandemic. Lancet Diabetes Endocrinol 9(10):643\u2013644","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"9291_CR33","doi-asserted-by":"crossref","first-page":"E44","DOI":"10.1152\/ajpendo.00244.2021","volume":"322","author":"CO de S\u00e1-Ferreira","year":"2022","unstructured":"de S\u00e1-Ferreira CO et al (2022) Diabetic ketoacidosis and COVID-19: what have we learned so far? Am J Physiol Endocrinol Metab 322(1):E44\u2013E53","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"9","key":"9291_CR34","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/oby.22923","volume":"28","author":"K Hajifathalian","year":"2020","unstructured":"Hajifathalian K et al (2020) Obesity is associated with worse outcomes in COVID-19: analysis of early data from New York City. Obesity (Silver Spring) 28(9):1606\u20131612","journal-title":"Obesity (Silver Spring)"},{"issue":"45","key":"9291_CR35","doi-asserted-by":"crossref","first-page":"67685","DOI":"10.1007\/s11356-022-22345-w","volume":"29","author":"I Kaur","year":"2022","unstructured":"Kaur I et al (2022) A motley of possible therapies of the COVID-19: reminiscing the origin of the pandemic. Environ Sci Pollut Res Int 29(45):67685\u201367703","journal-title":"Environ Sci Pollut Res Int"},{"key":"9291_CR36","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.784459","volume":"13","author":"CJ Bailey","year":"2022","unstructured":"Bailey CJ, Gwilt M (2022) Diabetes, metformin and the clinical course of COVID-19: outcomes, mechanisms and suggestions on the therapeutic use of metformin. Front Pharmacol 13:784459","journal-title":"Front Pharmacol"},{"issue":"3","key":"9291_CR37","volume":"15","author":"F Khan","year":"2023","unstructured":"Khan F et al (2023) Side effects of COVID-19 vaccines among diabetic subjects and healthy individuals. Cureus 15(3):e36005","journal-title":"Cureus"},{"issue":"2","key":"9291_CR38","volume":"6","author":"AC Kwan","year":"2023","unstructured":"Kwan AC et al (2023) Association of COVID-19 vaccination with risk for incident diabetes after COVID-19 infection. JAMA Netw Open 6(2):e2255965","journal-title":"JAMA Netw Open"},{"issue":"3","key":"9291_CR39","doi-asserted-by":"crossref","first-page":"356","DOI":"10.4093\/dmj.2022.0129","volume":"47","author":"HJ Kim","year":"2023","unstructured":"Kim HJ et al (2023) Safety of COVID-19 vaccines among patients with Type 2 diabetes mellitus: real-world data analysis. Diabetes Metab J 47(3):356\u2013365","journal-title":"Diabetes Metab J"},{"issue":"1","key":"9291_CR40","doi-asserted-by":"crossref","first-page":"14790","DOI":"10.1038\/s41598-020-71908-9","volume":"10","author":"X Lin","year":"2020","unstructured":"Lin X et al (2020) Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep 10(1):14790","journal-title":"Sci Rep"},{"issue":"2","key":"9291_CR41","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2020.10.002","volume":"47","author":"T Sathish","year":"2021","unstructured":"Sathish T et al (2021) Potential metabolic and inflammatory pathways between COVID-19 and new-onset diabetes. Diabetes Metab 47(2):101204","journal-title":"Diabetes Metab"},{"issue":"1","key":"9291_CR42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41574-020-00435-4","volume":"17","author":"S Lim","year":"2021","unstructured":"Lim S et al (2021) COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol 17(1):11\u201330","journal-title":"Nat Rev Endocrinol"},{"key":"9291_CR43","doi-asserted-by":"crossref","first-page":"1063519","DOI":"10.3389\/fgene.2022.1063519","volume":"13","author":"KCH Wu","year":"2022","unstructured":"Wu KCH et al (2022) Shared genetic mechanism between type 2 diabetes and COVID-19 using pathway-based association analysis. Front Genet 13:1063519","journal-title":"Front Genet"},{"issue":"1","key":"9291_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43042-022-00314-9","volume":"23","author":"A Pouremamali","year":"2022","unstructured":"Pouremamali A et al (2022) Understanding the pivotal roles of ACE2 in SARS-CoV-2 infection: from structure\/function to therapeutic implication. Egypt J Med Hum Genet 23(1):1\u201310","journal-title":"Egypt J Med Hum Genet"},{"issue":"1","key":"9291_CR45","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12933-021-01286-7","volume":"20","author":"N D'Onofrio","year":"2021","unstructured":"D\u2019Onofrio N et al (2021) Glycated ACE2 receptor in diabetes: open door for SARS-CoV-2 entry in cardiomyocyte. Cardiovasc Diabetol 20(1):99","journal-title":"Cardiovasc Diabetol"},{"key":"9291_CR46","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.109813","volume":"186","author":"B Pinchera","year":"2022","unstructured":"Pinchera B et al (2022) Diabetes and COVID-19: the potential role of mTOR. Diabetes Res Clin Pract 186:109813","journal-title":"Diabetes Res Clin Pract"},{"key":"9291_CR47","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154845","volume":"123","author":"SL Calvisi","year":"2021","unstructured":"Calvisi SL et al (2021) Thromboembolism risk among patients with diabetes\/stress hyperglycemia and COVID-19. Metabolism 123:154845","journal-title":"Metabolism"},{"issue":"5","key":"9291_CR48","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s10096-020-04138-6","volume":"40","author":"S Beyerstedt","year":"2021","unstructured":"Beyerstedt S, Casaro EB, Rangel B (2021) COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis 40(5):905\u2013919","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"11","key":"9291_CR49","doi-asserted-by":"crossref","first-page":"6465","DOI":"10.1016\/j.sjbs.2021.07.003","volume":"28","author":"A Elshafei","year":"2021","unstructured":"Elshafei A et al (2021) RAAS, ACE2 and COVID-19; a mechanistic review. Saudi J Biol Sci 28(11):6465\u20136470","journal-title":"Saudi J Biol Sci"},{"issue":"4","key":"9291_CR50","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13733","volume":"233","author":"B Memon","year":"2021","unstructured":"Memon B, Abdelalim EM (2021) ACE2 function in the pancreatic islet: implications for relationship between SARS-CoV-2 and diabetes. Acta Physiol (Oxf) 233(4):e13733","journal-title":"Acta Physiol (Oxf)"},{"issue":"6","key":"9291_CR51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009634","volume":"17","author":"E Varghese","year":"2021","unstructured":"Varghese E et al (2021) Diabetes and coronavirus (SARS-CoV-2): molecular mechanism of Metformin intervention and the scientific basis of drug repurposing. PLoS Pathog 17(6):e1009634","journal-title":"PLoS Pathog"},{"issue":"5","key":"9291_CR52","first-page":"442","volume":"16","author":"A Berbudi","year":"2020","unstructured":"Berbudi A et al (2020) Type 2 diabetes and its impact on the immune system. Curr Diabetes Rev 16(5):442\u2013449","journal-title":"Curr Diabetes Rev"},{"issue":"2","key":"9291_CR53","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3390\/pathogens12020184","volume":"12","author":"S Dallavalasa","year":"2023","unstructured":"Dallavalasa S et al (2023) COVID-19: diabetes perspective\u2014pathophysiology and management. Pathogens 12(2):184","journal-title":"Pathogens"},{"key":"9291_CR54","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155236","volume":"133","author":"J Shin","year":"2022","unstructured":"Shin J et al (2022) SARS-CoV-2 infection impairs the insulin\/IGF signaling pathway in the lung, liver, adipose tissue, and pancreatic cells via IRF1. Metabolism 133:155236","journal-title":"Metabolism"},{"issue":"4","key":"9291_CR55","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/jmv.26728","volume":"93","author":"BS Karam","year":"2021","unstructured":"Karam BS et al (2021) mTOR inhibition in COVID-19: a commentary and review of efficacy in RNA viruses. J Med Virol 93(4):1843\u20131846","journal-title":"J Med Virol"},{"issue":"12","key":"9291_CR56","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1038\/s41366-020-00670-9","volume":"44","author":"SK Ganesan","year":"2020","unstructured":"Ganesan SK et al (2020) Increased mortality of COVID-19 infected diabetes patients: role of furin proteases. Int J Obes 44(12):2486\u20132488","journal-title":"Int J Obes"},{"key":"9291_CR57","doi-asserted-by":"crossref","unstructured":"Brouwers B et al (2020) Furin controls \u03b2 cell function via mTORC1 signaling. bioRxiv 2020.04.09.027839","DOI":"10.1101\/2020.04.09.027839"},{"issue":"2S","key":"9291_CR58","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1097\/TP.0000000000001693","volume":"102","author":"A Kurdi","year":"2018","unstructured":"Kurdi A, Martinet W, De Meyer GR (2018) mTOR inhibition and cardiovascular diseases: dyslipidemia and atherosclerosis. Transplantation 102(2S):S44\u2013S46","journal-title":"Transplantation"},{"issue":"3","key":"9291_CR59","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/ncpendmet1066","volume":"5","author":"AD Mooradian","year":"2009","unstructured":"Mooradian AD (2009) Dyslipidemia in type 2 diabetes mellitus. Nat Rev Endocrinol 5(3):150\u2013159","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"9291_CR60","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.dsx.2020.07.054","volume":"14","author":"TI Hariyanto","year":"2020","unstructured":"Hariyanto TI, Kurniawan A (2020) Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr Clin Res Rev 14(5):1463\u20131465","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"9291_CR61","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1007\/s00705-021-05070-6","volume":"166","author":"SMA Hashemi","year":"2021","unstructured":"Hashemi SMA et al (2021) Human gene polymorphisms and their possible impact on the clinical outcome of SARS-CoV-2 infection. Arch Virol 166:2089\u20132108","journal-title":"Arch Virol"},{"issue":"28","key":"9291_CR62","doi-asserted-by":"crossref","first-page":"8327","DOI":"10.12998\/wjcc.v9.i28.8327","volume":"9","author":"S Sen","year":"2021","unstructured":"Sen S et al (2021) Diabetes mellitus and COVID-19: understanding the association in light of current evidence. World J Clin Cases 9(28):8327","journal-title":"World J Clin Cases"},{"issue":"1","key":"9291_CR63","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.pcd.2020.08.018","volume":"15","author":"S Sayed","year":"2021","unstructured":"Sayed S (2021) COVID-19 and diabetes; possible role of polymorphism and rise of telemedicine. Prim Care Diabetes 15(1):4\u20139","journal-title":"Prim Care Diabetes"},{"key":"9291_CR64","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.955965","volume":"13","author":"A Faridzadeh","year":"2022","unstructured":"Faridzadeh A et al (2022) The role of ACE1 I\/D and ACE2 polymorphism in the outcome of Iranian COVID-19 patients: a case\u2013control study. Front Genet 13:955965","journal-title":"Front Genet"},{"key":"9291_CR65","doi-asserted-by":"crossref","DOI":"10.1016\/j.imu.2020.100407","volume":"20","author":"N Balmeh","year":"2020","unstructured":"Balmeh N et al (2020) Predicted therapeutic targets for COVID-19 disease by inhibiting SARS-CoV-2 and its related receptors. Inform Med Unlocked 20:100407","journal-title":"Inform Med Unlocked"},{"issue":"3","key":"9291_CR66","doi-asserted-by":"crossref","DOI":"10.1016\/j.phyplu.2022.100280","volume":"2","author":"AP Yusuf","year":"2022","unstructured":"Yusuf AP et al (2022) Herbal medications and natural products for patients with covid-19 and diabetes mellitus: potentials and challenges. Phytomed Plus 2(3):100280","journal-title":"Phytomed Plus"},{"issue":"17","key":"9291_CR67","doi-asserted-by":"crossref","first-page":"6792","DOI":"10.1080\/07391102.2020.1803968","volume":"39","author":"P Chowdhury","year":"2021","unstructured":"Chowdhury P (2021) In silico investigation of phytoconstituents from Indian medicinal herb \u2018Tinospora cordifolia (giloy)\u2019 against SARS-CoV-2 (COVID-19) by molecular dynamics approach. J Biomol Struct Dyn 39(17):6792\u20136809","journal-title":"J Biomol Struct Dyn"},{"issue":"2","key":"9291_CR68","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2478\/hepo-2022-0006","volume":"68","author":"R Panchamoorthy","year":"2022","unstructured":"Panchamoorthy R, Prabhakar P (2022) Mucormycosis, a post-COVID infection: possible adjunctive herbal therapeutics for the realigning of impaired immune-metabolism in diabetic subjects. Herba Pol 68(2):86\u201398","journal-title":"Herba Pol"},{"key":"9291_CR69","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2021.100115","volume":"11","author":"M Aucoin","year":"2021","unstructured":"Aucoin M et al (2021) A systematic review on the effects of Echinacea supplementation on cytokine levels: is there a role in COVID-19? Metab Open 11:100115","journal-title":"Metab Open"},{"issue":"4","key":"9291_CR70","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.aimed.2020.07.004","volume":"7","author":"M Aucoin","year":"2020","unstructured":"Aucoin M et al (2020) The effect of Echinacea spp. on the prevention or treatment of COVID-19 and other respiratory tract infections in humans: a rapid review. Adv Integr Med 7(4):203\u2013217","journal-title":"Adv Integr Med"},{"issue":"6","key":"9291_CR71","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/08916930500221761","volume":"38","author":"D Delorme","year":"2005","unstructured":"Delorme D, Miller SC (2005) Dietary consumption of Echinacea by mice afflicted with autoimmune (Type I) diabetes: effect of consuming the herb on hemopoietic and immune cell dynamics. Autoimmunity 38(6):453\u2013461","journal-title":"Autoimmunity"},{"issue":"2","key":"9291_CR72","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/jphp.12676","volume":"69","author":"T Behl","year":"2016","unstructured":"Behl T, Kotwani A (2016) Proposed mechanisms of Terminalia catappa in hyperglycaemia and associated diabetic complications. J Pharm Pharmacol 69(2):123\u2013134","journal-title":"J Pharm Pharmacol"},{"issue":"8","key":"9291_CR73","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3390\/molecules21081026","volume":"21","author":"MT Akhtar","year":"2016","unstructured":"Akhtar MT et al (2016) Anti-diabetic activity and metabolic changes induced by Andrographis paniculata plant extract in obese diabetic rats. Molecules 21(8):1026","journal-title":"Molecules"},{"key":"9291_CR74","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.155018","volume":"119","author":"T Siripongboonsitti","year":"2023","unstructured":"Siripongboonsitti T et al (2023) Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: a double-blind, randomized, placebo-controlled study (APFaVi trial). Phytomedicine 119:155018","journal-title":"Phytomedicine"},{"issue":"27","key":"9291_CR75","doi-asserted-by":"crossref","first-page":"35429","DOI":"10.1007\/s11356-021-14480-7","volume":"28","author":"S Kashyap","year":"2021","unstructured":"Kashyap S et al (2021) Uncurtaining the effect of COVID-19 in diabetes mellitus: a complex clinical management approach. Environ Sci Pollut Res 28(27):35429\u201335436","journal-title":"Environ Sci Pollut Res"},{"key":"9291_CR76","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.581840","volume":"11","author":"D Silveira","year":"2020","unstructured":"Silveira D et al (2020) COVID-19: is there evidence for the use of herbal medicines as adjuvant symptomatic therapy? Front Pharmacol 11:581840","journal-title":"Front Pharmacol"},{"key":"9291_CR77","doi-asserted-by":"crossref","first-page":"5525165","DOI":"10.1155\/2023\/5525165","volume":"2023","author":"S Bafandeh","year":"2023","unstructured":"Bafandeh S et al (2023) Natural products as a potential source of promising therapeutics for COVID-19 and viral diseases. Evid Based Complement Altern Med 2023:5525165","journal-title":"Evid Based Complement Altern Med"},{"issue":"9","key":"9291_CR78","first-page":"1934578X2211263","volume":"17","author":"N Sharma","year":"2022","unstructured":"Sharma N et al (2022) Therapeutic options for the SARS-CoV-2 virus: is there a key in herbal medicine? Nat Prod Commun 17(9):1934578X221126303","journal-title":"Nat Prod Commun"},{"issue":"4","key":"9291_CR79","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3390\/molecules26041191","volume":"26","author":"CR Gomez","year":"2021","unstructured":"Gomez CR et al (2021) Therapeutic intervention of COVID-19 by natural products: a population-specific survey directed approach. Molecules 26(4):1191","journal-title":"Molecules"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-09291-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-024-09291-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-09291-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T21:01:46Z","timestamp":1738702906000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-024-09291-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["9291"],"URL":"https:\/\/doi.org\/10.1007\/s11033-024-09291-1","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,20]]},"assertion":[{"value":"26 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Ethical Committee of the Saveh University of Medical Sciences, Saveh, Iran.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"316"}}